May 28th 2021
By Tony Hagen
More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.
May 25th 2021
The pandemic interrupted health care for many patients and saddled health care institutions with high costs. How might biosimilars improve conditions?
May 12th 2021
With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit.
May 5th 2021
The anatomy of an interchangeability switching study.
May 4th 2021
By Skylar Jeremias
Biosimilar companies partnered with other companies and saw earnings increases, while reference product corporations faced sales erosion from biosimilar competition.
May 3rd 2021
There are multiple contenders now in the race to bring the first aflibercept (Eylea) biosimilar to market in the United States and European Union.
Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.
April 30th 2021
There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.
April 28th 2021
How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.
April 24th 2021
Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
